Health & Fitness
Fri, May 6, 2011Thu, May 5, 2011Wed, May 4, 2011Tue, May 3, 2011Mon, May 2, 2011Fri, April 29, 2011Thu, April 28, 2011Wed, April 27, 2011Tue, April 26, 2011Mon, April 25, 2011Fri, April 22, 2011Thu, April 21, 2011Wed, April 20, 2011Tue, April 19, 2011Mon, April 18, 2011Sun, April 17, 2011Fri, April 15, 2011Thu, April 14, 2011Wed, April 13, 2011Tue, April 12, 2011Mon, April 11, 2011Urologix to Host Its Fiscal 2011 Third Quarter Conference Call
Published in Health and Fitness on Wednesday, April 20th 2011 at 13:11 GMT by Market Wire
MINNEAPOLIS--([ BUSINESS WIRE ])--Urologix�, Inc. (Nasdaq:ULGX) will host a conference call to present fiscal 2011 third quarter results on Tuesday, April 26, 2011 at 4:00 p.m. CT, following the Companya�s post-market press release on the same day. On the day of the call, please dial 1-866-783-2144 and enter the Participant Passcode 98372867 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at [ www.urologix.com ]. Stryker Warren, Jr., Chief Executive Officer, will host the call.
Webcast listeners should log on at least 10 minutes prior to the scheduled start time of the call to register and download or install any required audio software. A replay of the call will be available until May 3, 2011 at 4:00 p.m. CT (5:00 p.m. ET). To listen to the replay, please dial 1-888-286-8010 and enter the Participant Passcode 59170187.
The webcast is also being distributed over CCBNa�s Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBNa�s individual investor center at [ www.companyboardroom.com ] or by visiting any of the investor sites in CCBNa�s Individual Investor Network. Institutional investors can access the call via CCBNa�s password-protected event management site, StreetEvents ([ www.streetevents.com ]).
About Urologix
Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia (BPH), a condition that affects more than 23 million men worldwide. Urologixa� products include the CoolWave� and Targis� control units and the CTC Advancea", Targis� and Prostaprobe� catheter families. All of Urologixa� products utilize Cooled ThermoTherapya"- targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort - and provide safe, effective, lasting relief of the symptoms of BPH.
